Tina M Gunderson1, Elena Myasoedova2, John M Davis3, Cynthia S Crowson4. 1. T.M. Gunderson, MS, Department of Health Sciences Research, Mayo Clinic, Rochester. 2. E. Myasoedova, MD, PhD, C.S. Crowson, PhD, Department of Health Sciences Research, and Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester. 3. J.M. Davis III, MD, MS, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. 4. E. Myasoedova, MD, PhD, C.S. Crowson, PhD, Department of Health Sciences Research, and Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester; crowson@mayo.edu.
Abstract
OBJECTIVE: To estimate the prevalence and incidence of multimorbidity (MM) in a population-based cohort of patients with rheumatoid arthritis (RA) compared to subjects without RA. METHODS: Between 1999-2013, residents of Olmsted County, Minnesota with incident RA who met the 1987 American College of Rheumatology criteria were compared to age- and sex-matched non-RA subjects from the same population. Twenty-five chronic comorbidities from a combination of the Charlson, Elixhauser, and Rheumatic Disease Comorbidity Indices were included, excluding rheumatic comorbidities. The Aalen-Johansen method was used to estimate the cumulative incidence of MM (MM2+; ≥ 2 chronic comorbidities) or substantial MM (MM5+; ≥ 5), adjusting for the competing risk of death. RESULTS: The study included 597 patients with RA and 594 non-RA subjects (70% female, 90% White, mean age 55.5 yrs). At incidence/index date, the prevalence of MM2+ was higher in RA than non-RA subjects (38% RA vs 32% non-RA, P = 0.02), whereas prevalence of MM5+ was similar (5% RA vs. 4% non-RA, P = 0.68). During follow-up (median 11.6 yrs RA, 11.3 yrs non-RA), more patients with RA developed MM2+ (214 RA vs 188 non-RA; adjusted HR 1.39, 95% CI 1.14-1.69). By 10 years after RA incidence/index, the cumulative incidence of MM2+ was 56.5% among the patients with RA (95% CI 56.5-62.3%) compared with 47.9% among the non-RA (95% CI 42.8-53.7%). Patients with RA showed no evidence of increase in incidence of MM5+ (adjusted HR 1.17, 95% CI 0.93-1.47). CONCLUSION: Patients with RA have both a higher prevalence of MM at the time of RA incidence as well as increased incidence thereafter.
OBJECTIVE: To estimate the prevalence and incidence of multimorbidity (MM) in a population-based cohort of patients with rheumatoid arthritis (RA) compared to subjects without RA. METHODS: Between 1999-2013, residents of Olmsted County, Minnesota with incident RA who met the 1987 American College of Rheumatology criteria were compared to age- and sex-matched non-RA subjects from the same population. Twenty-five chronic comorbidities from a combination of the Charlson, Elixhauser, and Rheumatic Disease Comorbidity Indices were included, excluding rheumatic comorbidities. The Aalen-Johansen method was used to estimate the cumulative incidence of MM (MM2+; ≥ 2 chronic comorbidities) or substantial MM (MM5+; ≥ 5), adjusting for the competing risk of death. RESULTS: The study included 597 patients with RA and 594 non-RA subjects (70% female, 90% White, mean age 55.5 yrs). At incidence/index date, the prevalence of MM2+ was higher in RA than non-RA subjects (38% RA vs 32% non-RA, P = 0.02), whereas prevalence of MM5+ was similar (5% RA vs. 4% non-RA, P = 0.68). During follow-up (median 11.6 yrs RA, 11.3 yrs non-RA), more patients with RA developed MM2+ (214 RA vs 188 non-RA; adjusted HR 1.39, 95% CI 1.14-1.69). By 10 years after RA incidence/index, the cumulative incidence of MM2+ was 56.5% among the patients with RA (95% CI 56.5-62.3%) compared with 47.9% among the non-RA (95% CI 42.8-53.7%). Patients with RA showed no evidence of increase in incidence of MM5+ (adjusted HR 1.17, 95% CI 0.93-1.47). CONCLUSION: Patients with RA have both a higher prevalence of MM at the time of RA incidence as well as increased incidence thereafter.
Authors: Elena Myasoedova; Sherine E Gabriel; Eric L Matteson; John M Davis; Terry M Therneau; Cynthia S Crowson Journal: J Rheumatol Date: 2017-04-01 Impact factor: 4.666
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Am J Epidemiol Date: 2011-03-23 Impact factor: 4.897
Authors: Hilal Maradit-Kremers; Cynthia S Crowson; Paulo J Nicola; Karla V Ballman; Véronique L Roger; Steve J Jacobsen; Sherine E Gabriel Journal: Arthritis Rheum Date: 2005-02
Authors: Elena Nikiphorou; Sam Norton; Lewis Carpenter; Josh Dixey; David Andrew Walsh; Patrick Kiely; Adam Young Journal: Arthritis Care Res (Hoboken) Date: 2016-11-21 Impact factor: 4.794
Authors: Hilal Maradit Kremers; Michelle Bidaut-Russell; Christopher G Scott; Megan S Reinalda; Alan R Zinsmeister; Sherine E Gabriel Journal: J Rheumatol Date: 2003-09 Impact factor: 4.666
Authors: Kazuki Yoshida; Tzu-Chieh Lin; Melissa Y Wei; Susan Malspeis; Su H Chu; Carlos A Camargo; Benjamin A Raby; Hyon K Choi; Sara K Tedeschi; Medha Barbhaiya; Bing Lu; Karen H Costenbader; Elizabeth W Karlson; Jeffrey A Sparks Journal: Arthritis Care Res (Hoboken) Date: 2021-02 Impact factor: 4.794
Authors: Maxime Dougados; Martin Soubrier; Anna Antunez; Peter Balint; Alejandro Balsa; Maya H Buch; Gustavo Casado; Jacqueline Detert; Bassel El-Zorkany; Paul Emery; Najia Hajjaj-Hassouni; Masayoshi Harigai; Shue-Fen Luo; Reka Kurucz; Gabriel Maciel; Emilio Martin Mola; Carlo Maurizio Montecucco; Iain McInnes; Helga Radner; Josef S Smolen; Yeong-Wook Song; Harald Erwin Vonkeman; Kevin Winthrop; Jonathan Kay Journal: Ann Rheum Dis Date: 2013-10-04 Impact factor: 19.103
Authors: Cynthia S Crowson; Tina M Gunderson; Hayley J Dykhoff; Elena Myasoedova; Elizabeth J Atkinson; Vanessa L Kronzer; Caitrin M Coffey; John M Davis Iii Journal: RMD Open Date: 2022-01